docetaxel + selinexor

Docetaxel + selinexor is an investigational combination therapy consisting of docetaxel, a microtubule inhibitor, and selinexor, an oral selective inhibitor of nuclear export (SINE) targeting exportin 1 (XPO1). Docetaxel disrupts microtubule dynamics leading to cell cycle arrest and apoptosis. Selinexor blocks XPO1-mediated nuclear export of tumor suppressor proteins, resulting in their accumulation in the nucleus and enhanced tumor cell death. This combination has been studied primarily for advanced KRAS-mutant non-small cell lung cancer (NSCLC), showing moderate efficacy with manageable toxicity in early-phase clinical trials[1][2][3]. The regimen is being evaluated for its potential to overcome resistance mechanisms associated with KRAS mutations.